Skip to main content
  • Investors
  • Mediaopen in a new window
  • Contact Usopen in a new window
  • |
Ironwood Logoopen in a new window
  • Company
  • Science & Medicine
  • Patients
  • Responsibility
  • Careers
  • IR Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
    • Governance Documents
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials
    • Quarterly Results
    • Annual Reports
    • SEC Filings
  • Investor FAQs
  • Press Releases
  • Investor Contacts
    • Investor Emails Alerts
    • RSS Feeds
  • IR Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
    • Governance Documents
    • Executive Management
    • Board of Directors
    • Committee Composition
    • Contact the Board
  • Financials
    • Quarterly Results
    • Annual Reports
    • SEC Filings
  • Investor FAQs
  • Press Releases
  • Investor Contacts
    • Investor Emails Alerts
    • RSS Feeds
Close
Close
  • Investors
  • Company
  • Product
  • Research & Development
  • Patients
  • Partnerships
  • Careers
Close

Press Releases

Normal
Press Release RSS Feed (opens in new window)
Press release year list 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008
December 16, 2022
AbbVie Submits Supplemental New Drug Application to U.S. FDA to Support New Indication of LINZESS® (linaclotide) for Functional Constipation in Children and Adolescents 6 to 17 Years of Age
November 22, 2022
Ironwood Pharmaceuticals to Participate in the Piper Sandler 34th Annual Healthcare Conference
November 3, 2022
Ironwood Pharmaceuticals Reports Strong Third Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
October 20, 2022
Ironwood Pharmaceuticals to Host Third Quarter 2022 Investor Update Call
September 6, 2022
Ironwood Pharmaceuticals Reports Positive Topline Data from Phase III Trial of LINZESS® (linaclotide) in Pediatric Patients Aged 6-17 with Functional Constipation
September 1, 2022
Ironwood Pharmaceuticals to Present at the 2022 Wells Fargo Healthcare Conference
August 4, 2022
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
July 21, 2022
Ironwood Pharmaceuticals to Host Second Quarter 2022 Investor Update Call
May 25, 2022
Ironwood Presents New Data Demonstrating Potential of IW-3300 for Visceral Pain at Digestive Disease Week® (DDW) 2022
May 9, 2022
Ironwood Pharmaceuticals to Present New IW-3300 and Linaclotide Data at Digestive Disease Week® 2022
May 5, 2022
Ironwood Pharmaceuticals Reports First Quarter 2022 Results; Maintains Full Year 2022 Financial Guidance
April 21, 2022
Ironwood Pharmaceuticals to Host First Quarter 2022 Investor Update Call
March 2, 2022
Ironwood Pharmaceuticals to Present at Upcoming Investor Conferences
February 17, 2022
Ironwood Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Results; LINZESS® (linaclotide) Achieves Blockbuster Status as U.S. Net Sales Exceed $1 Billion in 2021
February 3, 2022
Ironwood Pharmaceuticals to Host Fourth Quarter and Full Year 2021 Investor Update Call
January 10, 2022
Ironwood Pharmaceuticals Provides Update on FY 2021 Financial Guidance and Announces FY 2022 Financial Guidance
January 5, 2022
Ironwood Pharmaceuticals to Present at the 40th Annual J.P. Morgan Healthcare Conference

Investor Alerts

To opt-in for investor email alerts, please enter your email address in the field below and select at least one alert option. After submitting your request, you will receive an activation email to the requested email address. You must click the activation link in order to complete your subscription. You can sign up for additional alert options at any time.

At Ironwood Pharmaceuticals, Inc., we strive to treat your data with respect and will not share your information with any third party. You can unsubscribe to any of the investor alerts you are subscribed to by visiting the ‘unsubscribe’ section below. If you experience any issues with this process, please contact us for further assistance.

By providing your email address below, you are providing consent to Ironwood Pharmaceuticals, Inc. to send you the requested Investor Email Alert updates.

* Required

*
*





Email Alert Sign Up Confirmation

Ironwood Logoopen in a new window
  • Investors
  • Media
  • Contact us
Follow us on Linkedin Follow us on Twitter

COMPANY

  • Company Overview
  • Leadership
  • Open Payments & Transparecy

PRODUCT

  • Linzees

RESEARCH & DEVELOPMENT

  • Pipeline
  • Medical Affairs

PARTNERSHIPS

  • Overview
  • Grants

PATIENTS

  • Overview

RESPONSBILITY

  • Overview
  • Community Giving
  • Equity,Diversity & Inclusion
  • Sustainability
  • Safety & Compliance
  • Patients & Research

CAREERS

  • Working at Ironwood
  • Open Positions
  • Internships, Co-ops & Fellowships

INVESTORS

  • Home
  • Why Invest
  • Events & Presentations
  • Corporate Governance
  • Finanical Information
  • Investor FAQ
  • Press Releases
  • Investor Contacts
  • Copyright © Ironwood. All rights reserved Powered By Q4 Inc. 5.77.0.2 (opens in new window)
  • Privacy Policy
  • California Privacy Policy
  • Site Map
  • Terms of Use